G Bolis
Overview
Explore the profile of G Bolis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
118
Citations
948
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Uberti F, Lattuada D, Morsanuto V, Nava U, Bolis G, Vacca G, et al.
J Clin Endocrinol Metab
. 2013 Nov;
99(4):1367-74.
PMID: 24285680
Context: Recently, vitamin D (VitD) has been recognized as increasingly importance in many cellular functions of several tissues and organs other than bone. In particular, VitD showed important beneficial effects...
2.
Grossi E, Noli S, Scarfone G, Villa A, Parazzini F, Cipriani S, et al.
Eur J Gynaecol Oncol
. 2013 Jan;
33(6):615-6.
PMID: 23327056
Purpose Of Investigation: In this paper the authors have analyzed the long-term survival of women with Stage III ovarian cancer due to lymph node metastasis. Materials And Methods: This retrospective...
3.
Liverani C, Lattuada D, Mangano S, Pignatari C, Puglia D, Monti E, et al.
J Pediatr Adolesc Gynecol
. 2012 Jul;
25(4):e81-3.
PMID: 22840941
Background: Donovanosis is a chronic bacterial illness, progressive and indolent, which normally attacks the skin and mucous membranes in the genital and perigenital regions. Case: An 18-year-old pregnant female presented...
4.
Scarfone G, Bolis G
Ann Oncol
. 2006 Jun;
17 Suppl 5:v199-200.
PMID: 16807456
No abstract available.
5.
Bolis G, Danese S, Tateo S, Rabaiotti E, DAgostino G, Merisio C, et al.
Int J Gynecol Cancer
. 2006 Mar;
16 Suppl 1:74-8.
PMID: 16515571
To compare the effect of epidoxorubicin given for 4 months versus no treatment in the survival of patients with advanced ovarian cancer and complete pathologic response after first-line surgery and...
6.
van Wijk F, Aapro M, Bolis G, Chevallier B, van der Burg M, Poveda A, et al.
Ann Oncol
. 2003 Feb;
14(3):441-8.
PMID: 12598351
Background: Combination chemotherapy yields better response rates which do not always lead to a survival advantage. The aim of this study was to investigate whether the reported differences in the...
7.
van Wijk F, Lhomme C, Bolis G, Scotto di Palumbo V, Tumolo S, Nooij M, et al.
Eur J Cancer
. 2002 Dec;
39(1):78-85.
PMID: 12504662
The aim of this study was to investigate the efficacy and toxicity of carboplatin given as monotherapy in endometrial adenocarcinoma. Cisplatin is one of the most active drugs in gynaecological...
8.
Bolis G, Scarfone G, Sciatta C, Polverino G, Rosa C, Guarnerio P, et al.
Gynecol Oncol
. 2001 Dec;
83(3):477-80.
PMID: 11733958
Objective: The purpose of this study was to define the maximum tolerated dose (MTD) of topotecan given as escalating doses combined to a fixed dosage of carboplatin in late relapsing...
9.
Wagenaar H, Pecorelli S, Vergote I, Curran D, Wagener D, Kobierska A, et al.
Eur J Gynaecol Oncol
. 2001 Aug;
22(3):187-93.
PMID: 11501769
Objective: To investigate the clinical activity and toxicity of a combination chemotherapy consisting of cyclophosphamide (C), adriamycin (A) and cisplatin (P) for patients with primary adenocarcinoma of the Fallopian tube...
10.
Wagenaar H, Colombo N, Vergote I, Hoctin-Boes G, Zanetta G, Pecorelli S, et al.
Gynecol Oncol
. 2001 May;
81(3):348-54.
PMID: 11371121
Objective: To investigate tumor response rate and treatment toxicity of a modified combination chemotherapy consisting of bleomycin (B), methotrexate (M), and CCNU (C) for patients with locally advanced, squamous-cell carcinoma...